Matches in Wikidata for { <http://www.wikidata.org/entity/Q91632129> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- Q91632129 description "artículu científicu espublizáu n'avientu de 2018" @default.
- Q91632129 description "scientific article published on 17 December 2018" @default.
- Q91632129 description "wetenschappelijk artikel" @default.
- Q91632129 description "наукова стаття, опублікована в грудні 2018" @default.
- Q91632129 name "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phas" @default.
- Q91632129 name "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phas" @default.
- Q91632129 type Item @default.
- Q91632129 label "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phas" @default.
- Q91632129 label "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phas" @default.
- Q91632129 prefLabel "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phas" @default.
- Q91632129 prefLabel "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phas" @default.
- Q91632129 P1433 Q91632129-B484ED97-F2E3-401D-BCE5-2230E57A04D2 @default.
- Q91632129 P1476 Q91632129-C4EAA4D3-1288-4F83-B78B-241A0382E0DB @default.
- Q91632129 P2093 Q91632129-00C4C278-FC51-4461-A4ED-FCDFB60004D9 @default.
- Q91632129 P2093 Q91632129-3DA4F84C-7092-4ECF-B427-6B74C28CAFA3 @default.
- Q91632129 P2093 Q91632129-4A25232D-6DF8-4E59-AC61-088444BA5CE4 @default.
- Q91632129 P2093 Q91632129-5E223D0A-F84A-458C-BCB8-7749FB4A6E12 @default.
- Q91632129 P2093 Q91632129-60B8CAE4-C23D-432E-8B7B-BE84A479F173 @default.
- Q91632129 P2093 Q91632129-700EA7C6-E20A-4D29-8A2C-869EBEA276C9 @default.
- Q91632129 P2093 Q91632129-7DB18915-4325-4AB3-88DD-EBB428BF2AE5 @default.
- Q91632129 P2093 Q91632129-82388555-192C-41B3-A772-455F64D4B817 @default.
- Q91632129 P2093 Q91632129-82592018-8825-488E-AB02-5AA0646ACF24 @default.
- Q91632129 P2093 Q91632129-82D08832-5064-4A8A-9D20-634FC39BB279 @default.
- Q91632129 P2093 Q91632129-87C0DD28-EF08-4161-A291-2938EBE2C00D @default.
- Q91632129 P2093 Q91632129-8B6FC9BA-CFD1-4D46-85F8-F7F9FCF33C6C @default.
- Q91632129 P2093 Q91632129-9C331723-5AB5-48E9-8D71-11811199769F @default.
- Q91632129 P2093 Q91632129-A54F7B0D-8220-4654-A980-8656A8A8BF83 @default.
- Q91632129 P2093 Q91632129-AEAB2286-2AB0-4C1A-A790-B5A765F759FE @default.
- Q91632129 P2093 Q91632129-B8877319-7F36-441F-A3C9-E131450581AB @default.
- Q91632129 P2093 Q91632129-C757AEE2-83D3-408B-8C4C-4961912370EA @default.
- Q91632129 P2093 Q91632129-CF26D78A-7885-4DC6-9F0F-2C38EC958C49 @default.
- Q91632129 P2093 Q91632129-D0961466-5089-46EC-87AB-2F720B3E96CC @default.
- Q91632129 P2093 Q91632129-EA4F61B4-0B51-4A80-A752-00DB42E34CE7 @default.
- Q91632129 P304 Q91632129-1D17A44F-59F0-4655-97E2-92C2DC6D70A6 @default.
- Q91632129 P31 Q91632129-8BB913C6-8689-4481-BBBD-AAA273B0464D @default.
- Q91632129 P356 Q91632129-5D31C64D-6240-49C0-9021-9AAC03B61BB8 @default.
- Q91632129 P433 Q91632129-68E66A5A-3507-4D5C-8B09-825493DA35AA @default.
- Q91632129 P478 Q91632129-8B9F6FFA-9C3F-46C8-9510-53BF4981A480 @default.
- Q91632129 P50 Q91632129-7B6C1C42-0A3C-475E-B186-E9D8D44B325F @default.
- Q91632129 P50 Q91632129-C0F41234-BB85-484F-9B11-55B851860546 @default.
- Q91632129 P577 Q91632129-74530852-4512-4E72-9FCD-C82A5068BC11 @default.
- Q91632129 P698 Q91632129-28E616DF-E4BA-4F62-A2EC-AA317069FB51 @default.
- Q91632129 P921 Q91632129-DC99AEB8-D06A-4010-A45C-B371ACCBC31D @default.
- Q91632129 P356 J.NMD.2018.12.004 @default.
- Q91632129 P698 30770310 @default.
- Q91632129 P1433 Q1981326 @default.
- Q91632129 P1476 "Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study" @default.
- Q91632129 P2093 "Alan Pestronk" @default.
- Q91632129 P2093 "Ans T van der Ploeg" @default.
- Q91632129 P2093 "Barry J Byrne" @default.
- Q91632129 P2093 "Benedikt Schoser" @default.
- Q91632129 P2093 "Claude Desnuelle" @default.
- Q91632129 P2093 "Jaya Trivedi" @default.
- Q91632129 P2093 "Jean Pouget" @default.
- Q91632129 P2093 "John Vissing" @default.
- Q91632129 P2093 "Karl Eugen Mengel" @default.
- Q91632129 P2093 "Katherine Kacena" @default.
- Q91632129 P2093 "Loren D M Pena" @default.
- Q91632129 P2093 "NEO1 Investigator Group" @default.
- Q91632129 P2093 "Ozlem Goker-Alpan" @default.
- Q91632129 P2093 "Pascal Laforêt" @default.
- Q91632129 P2093 "Peter Young" @default.
- Q91632129 P2093 "Philip Van Damme" @default.
- Q91632129 P2093 "Raheel Shafi" @default.
- Q91632129 P2093 "Richard J Barohn" @default.
- Q91632129 P2093 "Shafeeq Ladha" @default.
- Q91632129 P2093 "Volker Straub" @default.
- Q91632129 P304 "167-186" @default.
- Q91632129 P31 Q13442814 @default.
- Q91632129 P356 "10.1016/J.NMD.2018.12.004" @default.
- Q91632129 P433 "3" @default.
- Q91632129 P478 "29" @default.
- Q91632129 P50 Q111420958 @default.
- Q91632129 P50 Q111421204 @default.
- Q91632129 P577 "2018-12-17T00:00:00Z" @default.
- Q91632129 P698 "30770310" @default.
- Q91632129 P921 Q725307 @default.